Home / Intelligence / Case Studies / Early P&MA Forecasting Support for a Pipeline Asset
Trinity provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research.
Geographic Scope: 
Client Situation
The client wanted to uncover the optimal launch strategy for their pipeline asset by understanding the current and future landscape across several inflammatory diseases to support indication prioritization.
Trinity’s Solution
Trinity conducted secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting and pricing benchmarks.
Trinity then ran a pipeline assessment to predict shifts within the landscape and evolution in P&MA benchmarks, and synthesized findings to deliver a comprehensive indication-by-indication achievable net pricing strategy for early P&MA forecasting inputs.
Deliverables
- Detailed XLS outlining current pricing and access status of competitor therapies including level of contracting and payer mix
- Pipeline analysis including likely price comparator, achievable net price and likely level of payer management
Project Outcomes & Impact
The key P&MA data that Trinity provided to inform inputs for the early P&MA forecast of the client’s pipeline asset enabled them to prioritize their development activities and launch strategy to optimize the commercial opportunity.
Related Intelligence
Blog
5 Key Trends in Global Market Access
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacting in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics […]
Read More
Briefs
Unlocking Environmental Sustainability Opportunities in the Life Sciences
The healthcare industry has long been known for its significant environmental impact, including contributing ~5% of total global emissions. As awareness of this impact has increased, life sciences companies are now actively committing to climate resilience and environmental sustainability through various initiatives, including net-zero commitments. Trinity Life Sciences has identified several recent trends driving this […]
Read More
Briefs
Global Dossiers in the Joint Clinical Assessment Era: Impacts and Implications
Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal products will go through the JCA process, followed by all orphan medicinal products from 2028 […]
Read More